Skip to main content

Safety and Efficacy of Terlipressin in Pediatric Distributive Shock: A Retrospective Analysis in 20 Children

Pediatric Drugs volume 19, pages 35–41 (2017)Cite this article

Abstract

Introduction

Data are still lacking about the use of terlipressin or vasopressin in the treatment of pediatric patients who are in a state of therapy-refractory shock.

Objective

The aim of this study was to evaluate the effect of terlipressin on hemodynamics in children with distributive shock and to describe any severe side effects.

Methods

Consecutive patients (n = 20) with catecholamine-resistant distributive shock who were treated with terlipressin were retrospectively enrolled in this study. We analyzed response in terms of mean arterial blood pressure, heart rate, vasoactive inotropic score (VIS), urinary output, and serum lactate.

Results

The hemodynamics of 12 children significantly improved within 6 h of commencing terlipressin (mean blood pressure increase of ≥20 % without VIS increase, or mean blood pressure increase of ≥10 % with VIS decrease of ≥10 %). The hemodynamics of eight patients did not improve, regardless of treatment dosage or duration. More children died in the responders group (n = 7 [58.3 %]) than in the non-responders group (n = 2 [25.0 %]), but this was not statistically significant. Two patients (one in each group) who received high dosages of terlipressin developed rhabdomyolysis. One case of Takotsubo cardiomyopathy was observed, which could be related to terlipressin.

Conclusions

Although treatment with terlipressin resulted in rapid positive hemodynamic responses in some children, it did not seem to have a positive effect in other pediatric patients. Therefore, the possible benefits of terlipressin should be always weighed against potential severe adverse effects.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Matok I, Leibovitch L, Vardi A, et al. Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock. Pediatr Crit Care Med. 2004;5(2):116–8.

    Article  PubMed  Google Scholar 

  2. Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, et al. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med. 2004;30(3):477–80. doi:10.1007/s00134-003-2114-3.

    Article  PubMed  Google Scholar 

  3. Zeballos G, Lopez-Herce J, Fernandez C, et al. Rescue therapy with terlipressin by continuous infusion in a child with catecholamine-resistant septic shock. Resuscitation. 2006;68(1):151–3. doi:10.1016/j.resuscitation.2005.06.016.

    Article  PubMed  Google Scholar 

  4. Filippi L, Gozzini E, Daniotti M, et al. Rescue treatment with terlipressin in different scenarios of refractory hypotension in newborns and infants. Pediatr Crit Care Med. 2011;12(6):e237–41. doi:10.1097/PCC.0b013e3181fe304c.

    Article  PubMed  Google Scholar 

  5. Jerath N, Frndova H, McCrindle BW, et al. Clinical impact of vasopressin infusion on hemodynamics, liver and renal function in pediatric patients. Intensive Care Med. 2008;34(7):1274–80. doi:10.1007/s00134-008-1055-2.

    CAS  Article  PubMed  Google Scholar 

  6. Masutani S, Senzaki H, Ishido H, et al. Vasopressin in the treatment of vasodilatory shock in children. Pediatr Int. 2005;47(2):132–6. doi:10.1111/j.1442-200x.2005.02043.x.

    CAS  Article  PubMed  Google Scholar 

  7. Matok I, Vard A, Efrati O, et al. Terlipressin as rescue therapy for intractable hypotension due to septic shock in children. Shock. 2005;23(4):305–10.

    CAS  Article  PubMed  Google Scholar 

  8. Rodriguez-Nunez A, Oulego-Erroz I, Gil-Anton J, et al. Continuous terlipressin infusion as rescue treatment in a case series of children with refractory septic shock. Ann Pharmacother. 2010;44(10):1545–53. doi:10.1345/aph.1P254.

    CAS  Article  PubMed  Google Scholar 

  9. Agrawal A, Singh VK, Varma A, et al. Intravenous arginine vasopressin infusion in refractory vasodilatory shock: a clinical study. Indian J Pediatr. 2012;79(4):488–93. doi:10.1007/s12098-011-0557-z.

    Article  PubMed  Google Scholar 

  10. Albanese J, Leone M, Delmas A, et al. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med. 2005;33(9):1897–902.

    CAS  Article  PubMed  Google Scholar 

  11. Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, et al. Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care. 2006;10(1):R20. doi:10.1186/cc3984.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Yildizdas D, Yapicioglu H, Celik U, et al. Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children. Intensive Care Med. 2008;34(3):511–7. doi:10.1007/s00134-007-0971-x.

    CAS  Article  PubMed  Google Scholar 

  13. Choong K, Bohn D, Fraser DD, et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. Am J Respir Crit Care Med. 2009;180(7):632–9. doi:10.1164/rccm.200902-0221OC.

    CAS  Article  PubMed  Google Scholar 

  14. Leone M, Albanese J, Delmas A, et al. Terlipressin in catecholamine-resistant septic shock patients. Shock. 2004;22(4):314–9.

    CAS  Article  PubMed  Google Scholar 

  15. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med. 2004;30(4):597–604. doi:10.1007/s00134-003-2094-3.

    Article  PubMed  Google Scholar 

  16. O’Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet. 2002;359(9313):1209–10. doi:10.1016/S0140-6736(02)08225-9.

    Article  PubMed  Google Scholar 

  17. Westphal M, Stubbe H, Sielenkamper AW, et al. Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med. 2003;29(2):301–8. doi:10.1007/s00134-002-1546-5.

    Article  PubMed  Google Scholar 

  18. Agrawal A, Singh VK, Varma A, et al. Therapeutic applications of vasopressin in pediatric patients. Indian Pediatr. 2012;49(4):297–305.

    Article  PubMed  Google Scholar 

  19. Delmas A, Leone M, Rousseau S, et al. Clinical review: vasopressin and terlipressin in septic shock patients. Crit Care. 2005;9(2):212–22. doi:10.1186/cc2945.

    Article  PubMed  Google Scholar 

  20. Leone M, Martin C. Rescue therapy in septic shock—is terlipressin the last frontier? Crit Care. 2006;10(2):131. doi:10.1186/cc4863.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Leone M, Martin C. Role of terlipressin in the treatment of infants and neonates with catecholamine-resistant septic shock. Best Pract Res Clin Anaesthesiol. 2008;22(2):323–33.

    CAS  Article  PubMed  Google Scholar 

  22. Meyer S, McGuire W, Gottschling S, et al. The role of vasopressin and terlipressin in catecholamine-resistant shock and cardio-circulatory arrest in children: review of the literature. Wien Med Wochenschr. 2011;161(7–8):192–203. doi:10.1007/s10354-010-0853-7.

    Article  PubMed  Google Scholar 

  23. Polito A, Parisini E, Ricci Z, et al. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive Care Med. 2012;38(1):9–19. doi:10.1007/s00134-011-2407-x.

    CAS  Article  PubMed  Google Scholar 

  24. Shivanna B, Rios D, Rossano J, et al. Vasopressin and its analogues for the treatment of refractory hypotension in neonates. Cochrane Database Syst Rev. 2013;3:CD009171. doi:10.1002/14651858.CD009171.pub2.

    Google Scholar 

  25. Neunhoeffer F, Renk H, Hofbeck M, et al. Safety, efficacy and response to a hydrocortisone rescue therapy protocol in children with refractory hypotension after cardiopulmonal bypass. Pediatr Cardiol. 2015;36(3):640–5. doi:10.1007/s00246-014-1059-3.

    CAS  Article  PubMed  Google Scholar 

  26. Graciano AL, Balko JA, Rahn DS, et al. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med. 2005;33(7):1484–91.

    Article  PubMed  Google Scholar 

  27. Akcan-Arikan A, Zappitelli M, Loftis LL, et al. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71(10):1028–35. doi:10.1038/sj.ki.5002231.

    CAS  Article  PubMed  Google Scholar 

  28. Pierce ST, Nickl N. Rhabdomyolysis associated with the use of intravenous vasopressin. Am J Gastroenterol. 1993;88(3):424–7.

    CAS  PubMed  Google Scholar 

  29. Rolla D, Cannella G, Ravetti JL. Toxic rhabdomyolysis induced by terlipressin infusion in a uraemic patient suffering from AA-type amyloidosis. Nephron. 1999;83(2):167–8. doi:10.1159/000045496.

    CAS  Article  PubMed  Google Scholar 

  30. Zimmer V, Lammert F. Terlipressin-induced skin necrosis and rhabdomyolysis. Am J Med Sci. 2010;340(6):506. doi:10.1097/MAJ.0b013e3181ee9873.

    Article  PubMed  Google Scholar 

  31. Hernandez LE. Takotsubo cardiomyopathy: how much do we know of this syndrome in children and young adults? Cardiol Young. 2014;24(4):580–92. doi:10.1017/S1047951114000080.

    Article  PubMed  Google Scholar 

  32. Di Micoli A, Buccione D, Degli Esposti D, et al. Terlipressin infusion induces Tako-Tsubo syndrome in a cirrhotic man with hepato-renal syndrome. Intern Emerg Med. 2011;6(5):437–40. doi:10.1007/s11739-011-0534-6.

    Article  PubMed  Google Scholar 

  33. Lu YY, Wei KC, Wu CS. Terlipressin-induced extensive skin necrosis: a case report and published work review. J Dermatol. 2012;39(10):866–8. doi:10.1111/j.1346-8138.2012.01595.x.

    Article  PubMed  Google Scholar 

  34. Ozel Coskun BD, Karaman A, Gorkem H, et al. Terlipressin-induced ischemic skin necrosis: a rare association. Am J Case Rep. 2014;15:476–9. doi:10.12659/AJCR.891084.

    Article  PubMed  Google Scholar 

  35. Sundriyal D, Kumar N, Patnaik I, et al. Terlipressin induced ischaemia of skin. BMJ Case Rep. 2013. doi:10.1136/bcr-2013-010050.

  36. Donnellan F, Cullen G, Hegarty JE, et al. Ischaemic complications of Glypressin in liver disease: a case series. Br J Clin Pharmacol. 2007;64(4):550–2. doi:10.1111/j.1365-2125.2007.02921.x.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Pediatric Cardiology, Pulmology and Pediatric Intensive Care Medicine, University Children’s Hospital, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany

    Jörg Michel, Michael Hofbeck, Gina Spiller, Hanna Renk, Matthias Kumpf & Felix Neunhoeffer

Authors
  1. Jörg Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Hofbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gina Spiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hanna Renk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthias Kumpf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Felix Neunhoeffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörg Michel.

Ethics declarations

Approval

The study protocol was approved by the Ethics Committee of Tuebingen University Hospital, Germany (189/2013R).

Funding

No funding was received for the conduct of this study.

Conflict of interest

Jörg Michel, Michael Hofbeck, Gina Spiller, Hanna Renk, Matthias Kumpf, and Felix Neunhoeffer have no conflicts of interest that might be relevant to the contents of this manuscript.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Michel, J., Hofbeck, M., Spiller, G. et al. Safety and Efficacy of Terlipressin in Pediatric Distributive Shock: A Retrospective Analysis in 20 Children. Pediatr Drugs 19, 35–41 (2017). https://doi.org/10.1007/s40272-016-0199-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-016-0199-8

Keywords

  • Arterial Blood Pressure
  • Systemic Inflammatory Response Syndrome
  • Serum Lactate
  • Takotsubo Cardiomyopathy
  • Terlipressin